Full-Time
Administrative Assistant
Updated on 8/23/2026
Gladstone Institutes
501-1,000 employees
Biomedical research institute advancing disease therapies
Compensation Overview
$28.53 - $33.57/hr
San Francisco, CA, USA
In Person
Onsite at the Mission Bay campus.
 Administrative & Executive Assistance (2) |
|---|
| , |
Get referred to Gladstone Institutes
See people who can refer or advise you
- A detail-oriented self-starter who can work independently with minimal supervision.
- Exceptional organizational skills and a proven ability to solve problems proactively.
- Excellent written and verbal communication skills with strong attention to grammar, spelling, and editing.
- Professional demeanor with strong interpersonal skills, including tact, discretion, and clear communication.
- Demonstrated sound judgment, the ability to meet tight deadlines, and a proactive approach to tasks.
- Ability to work effectively both independently and as part of a team.
- Strong attention to detail and commitment to accuracy.
- Ability to thrive in a fast-paced environment and adapt quickly to changing priorities.
- Experience managing complex calendars and scheduling logistics.
- Proven ability to follow detailed instructions with a high degree of accuracy.
- Strong multitasking and prioritization skills.
- Advanced proficiency in Microsoft Word, Excel, and PowerPoint for Mac OS X, with a willingness to learn new software as needed.
- Coordinate travel arrangements and prepare detailed itineraries. Maintain accurate travel records, process reimbursement requests, and track as needed.
- Maintain investigators’ calendars. Schedule meetings and appointments, including proactively resolving scheduling conflicts and arranging meeting space, refreshments, and transportation, as appropriate.
- Communicate regularly with lab staff to assess supply needs. Coordinate with vendors, Procurement, and Accounting to ensure timely and cost-effective purchases. Resolve discrepancies as needed.
- Word process, format, organize, proofread, and correct correspondence, manuscripts, bibliographies, grants, fellowship applications, and other documents as required. Accurately read and follow grant and fellowship application procedures and formats.
- Coordinate weekly institute seminars and special events by arranging travel for guest speakers, reserving venues, ordering catering, and managing related logistics.
- Facilitate communication with administrative offices, including Accounting, Grants, Human Resources, Philanthropy, IT, Executive Office, and Facilities/Operations. Function as an external liaison with universities, research institutes, and government agencies, as appropriate.
- Provide departmental support to postdoctoral scholars and graduate students.
- Establish and maintain computerized templates, forms, and up-to-date standard grant sections, including Resources and Environment, Biographical Sketch, and Other Support.
- Maintain laboratory websites by regularly updating content.
- Maintain accurate records and an efficient filing system for easy access to key information.
- Support two investigators and diverse initiatives as a member of the administrative team at the Gladstone Institute of Neurological Disease.
- Coordinate events and seminars.
- Assist with manuscript submissions.
- Prepare and edit grant applications and manuscripts.
- Perform other duties as assigned.
- Experience creating and formatting tables in Microsoft Office.
- Experience supporting research faculty, investigators, or scientific teams.
- Experience preparing or editing grants, manuscripts, or fellowship applications.
- Experience coordinating seminars, meetings, or special events.
- Familiarity with maintaining laboratory or departmental websites.
Gladstone Institutes conducts biomedical research in areas such as cardiovascular disease, HIV, dementia, and diseases of the brain and eye. It runs basic and translational science programs to understand disease mechanisms and develop therapies, using techniques like CRISPR gene editing and stem cell research, often in collaboration with UCSF. Its work is organized around centers and directorates, with an emphasis on team-based investigation and training. Unlike many industry-funded firms, Gladstone is a nonprofit research institute that relies on philanthropy and partnerships to push scientific discoveries toward medical advances. The goal is to use science and technology to overcome major unsolved diseases and improve human health.
Company Size
501-1,000
Company Stage
Grant
Total Funding
$250K
Headquarters
San Francisco, California
Founded
1979
Get referred to Gladstone Institutes
See people who can refer or advise you
Simplify's Take
What believers are saying
- Gladstone leased 105,000 square feet in March 2026, securing room for growth.
- The $350 million Gladstone NOW campaign had raised about $200 million by March 2026.
- NIAID awarded $10.2 million over five years for Gladstone's PhAIge Therapy Center.
What critics are saying
- About $80 million of Gladstone's $125 million budget came from NIH in 2026.
- Deepak Srivastava said funding dropped 10% last year, forcing philanthropy to fill gaps.
- If federal cuts deepen through 2027, Gladstone's expansion and hiring plan stalls.
What makes Gladstone Institutes unique
- Gladstone pairs UCSF science with AI-driven genomics, immunology, and CRISPR platforms.
- Its 2026 PhAIge Therapy Center targets ESKAPE pathogens with predictive phage engineering.
- Mission Bay co-location at 1450 Owens Street concentrates 20 labs and 300 scientists.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Commuter Benefits
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%Gladstone Institutes receives National Recognition for Excellence in postdoc programs. Postdoctoral researchers are central to Gladstone's scientific mission, helping drive discoveries that advance the understanding and treatment of disease. Gladstone Institutes has been selected as one of 12 institutions nationwide to receive an Institutional Policy Award from the National Postdoctoral Association's new Excellence Recognition Program. The honor highlights Gladstone's strong alignment with the association's rigorous recommended policies and practices for supporting postdoctoral scholars through mentorship, professional development, workplace policies, and career advancement. "At Gladstone, we recognize that our postdoctoral scholars are primary engines of scientific advancement," says Deepak Srivastava, MD, president of Gladstone Institutes. "They are pushing the boundaries of what's possible and turning ambitious hypotheses into life-saving discoveries. Their success is, quite literally, Gladstone's success." Indeed, postdoctoral researchers are central to Gladstone's scientific mission, helping drive discoveries that advance the understanding and treatment of disease. Gladstone trains well over 100 postdoctoral scholars annually, with support spanning every stage of the training experience. Through its Postdoctoral and Graduate Student Education and Research Development Affairs office, Gladstone provides extensive professional development training, individualized career counseling, leadership development, grant and manuscript writing support, and career exploration resources. Postdoctoral scholars also benefit from structured mentoring practices, including annual individual development plans, mentor and mentee standards, and opportunities to build strong professional networks across the organization. Gladstone supports more than 100 postdoctoral scholars each year with mentorship, professional development, and career resources that help prepare the next generation of scientific leaders. "Our commitment to postdocs goes far beyond simply providing research training," says Sudha Krishnamurthy, PhD, director of Postdoctoral and Graduate Student Education and Research Development Affairs at Gladstone. "We aim to develop the whole scientist - ensuring they have the technical rigor, leadership skills, and mentorship network necessary to become the next generation of global leaders in biomedicine." Gladstone's postdocs go on to become research investigators, educators, life science industry professionals, government workers, and more, Krishnamurthy adds. The policies and programs at Gladstone recognized by the National Postdoctoral Association include transparent compensation practices, comprehensive employee benefits, dedicated services for international scholars, and resources that support mental health and well-being. "Improving the postdoctoral experience is a community effort," says Erin Heckler, PhD, vice chair of the National Postdoctoral Association's board of directors. "The NPA, recognizing the work of these institutions as examples of policies and practices, shares what progress is possible for everyone." The Institutional Policy Award acknowledges Gladstone's efforts to create a training environment where early-career scientists can develop the skills, experience, and professional networks needed to make impactful discoveries and become future leaders in biomedical research. For Media Julie Langelier Associate Director, Communications 415.734.5000 Email About Gladstone Institutes Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.
Can AI help us age better? Bay Area scientists are trying to find out. By Panashe Matemba-Mutasa, The Mercury News The Tribune Content Agency June 17, 2026 12:57 PM Gift Article A growing number of researchers are turning to artificial intelligence to understand why some people remain healthy into their 90s while others develop chronic diseases decades earlier. At labs throughout the Bay Area, the technology is fueling a wave of longevity research aimed at measuring how long people live - and how well they age. Researchers say AI can uncover early signs of age-related diseases, predict an individual's biological age and identify factors contributing to healthier lives - all by sifting through vast amounts of data to find patterns nearly impossible for humans to detect. The tools are still being refined. But scientists believe they could accelerate discoveries to improve health and independence into older adulthood. The most ambitious applications of AI in aging research, including speeding drug development and testing, remain years away, experts said. Researchers must also navigate bias within systems trained on data that may not reflect the full diversity of the population. Still, patients are already seeing some benefits, such as AI-assisted scan readings that can reduce the odds of false positives. "We're already seeing the benefits," said Nathan Price, chief scientist at the Buck Institute for Research on Aging in Novato. Any discovery won't be an anti-aging silver bullet. Social, behavioral and structural factors - including whether patients can access or choose to use those treatments - will play an equally important role, said Angie Perone, the director of the Center for the Advanced Study of Aging Services at UC Berkeley. "This is only one piece of an important puzzle," Perone said. Predicting how cells age. Scientists at Gladstone Institutes, based in San Francisco, recently launched an AI model to predict how human cells evolve with age. Trained on millions of cells, the model attempts to map the trajectory of aging, allowing researchers to forecast how cells might change and identify potential drivers of age-related decline. That marks a shift from earlier approaches, which largely compared snapshots of "young" and "old" cells. Instead, the model, developed by scientists led by physician-scientist Christina Theodoris, treats aging as a continuous process that can be learned and predicted. The team also tested some of the model's predictions in biological systems, identifying genes expected to accelerate aging and validating those effects in human heart cells and in mice. That kind of experimental follow-up is essential, experts say, though the research remains in early stages. "The real test will be whether these predictions hold up across many tissues and disease contexts," said Hani Goodarzi, a core investigator at Palo Alto-based Arc Institute, noting current tools, including animal models, are imperfect benchmarks. Significant hurdles remain. The model will require large-scale datasets that track how cells respond to drugs and genetic changes, along with validation across a wider range of tissues and diseases. And even the most accurate predictions must ultimately be translated into real-world therapies. Searching for hidden patterns. At the Buck Institute for Research on Aging, scientists are using artificial intelligence to figure out how to help people stay healthier for longer. One of the institute's AI projects integrates individual genetic information, clinical lab results, microbiome data and other health measurements. Drawing on a database containing thousands of biological measurements from research participants, the system identifies patterns and generates personalized insights about health risks and interventions. "The microbiome is highly predictive of who will lose weight," Price said, noting that AI can uncover connections hidden within vast datasets. Users can interact with the platform through a chatbot-like interface that generates graphs, health scores and detailed analyses of their data. They expect the tool to be released to the public by the end of the year. It is part of Healthspan Horizons, a large-scale research initiative supported by a $52 million grant that aims to enroll thousands of participants and better understand the biology of aging on an individual level. Detecting disease earlier. Artificial intelligence is also reshaping the way researchers study Alzheimer's disease by shifting the focus from symptoms to the biological changes occurring inside the brain. Rather than relying primarily on memory loss and other cognitive symptoms, AI is helping scientists analyze complex brain scans and other data to identify those changes earlier and more objectively. "The way we see Alzheimer's has shifted from seeing it as a clinical cognitive syndrome to a more biological disease," said Duygu Tosun-Turgut, a professor of radiology and biomedical imaging at UC San Francisco and founding director of Medical Imaging Informatics and Artificial Intelligence at the San Francisco Veterans Affairs Medical Center. That capability is particularly valuable for clinical trials. Before, researchers sometimes enrolled patients whose symptoms resembled Alzheimer's but were caused by other conditions, making it harder to determine whether experimental treatments were effective. AI can help identify people with the disease's true biological signatures, improving both patient selection and trial outcomes. Beyond research, Turgut believes AI could improve access to dementia screening and diagnosis, particularly in underserved communities. Specialized memory clinics remain scarce in many parts of the country, and studies have shown that dementia is often underdiagnosed among people with lower socioeconomic status. "Hopefully, we can develop tools that are cheap and scalable enough to be distributed to every geographic spot in the world," she said. Still, she and other researchers cautioned that AI systems are only as good as the data used to train them. Many research cohorts are disproportionately composed of highly educated participants and may not reflect the demographic diversity of the broader population. And so the promise of AI hinges on a hurdle researchers have yet to fully overcome: bias. Until these systems can consistently produce accurate, equitable results across diverse populations, human oversight remains essential. Still, scientists and startups are betting that AI will play an increasingly central role in unraveling the biology of aging, and, perhaps one day, extending healthy years of life.
Gladstone Institutes receives USD 2m NIAID award for AI-guided phage therapy development. May 20, 2026 Gladstone Institutes has received a USD 2 million NIAID P01 award to establish the PhAIge Therapy Center, a multi-project preclinical program applying AI-guided engineering and molecular typing to accelerate phage therapy development against multidrug-resistant ESKAPE pathogens, with an initial focus on Klebsiella pneumoniae. The five-year grant, running through April 2031, funds two research projects and three supporting cores under principal investigator Seth Lawler Shipman. The first project develops high-throughput, sequencing-based assays to quantify rate constants across each stage of the phage infection cycle - recognition, entry, replication, packaging, and lysis - generating the granular kinetic data needed to rationally select and engineer phages with superior bactericidal activity. The second project uses multiplexed assays to rapidly characterize K. pneumoniae strains by capsule type and susceptibility profile, enabling construction of optimized, off-the-shelf phage cocktails matched to individual clinical isolates. Two specialized cores anchor the translational infrastructure. An Advanced Computational Core integrates bioinformatics pipelines, machine learning, and AI-driven modeling to predict phage-host interactions and guide candidate selection. An Organoid and Human Cell Culture Core incorporates 3D human tissue models and primary cell cultures into early screening, capturing host-pathogen dynamics that standard in vitro assays do not reflect. The program also includes an Administrative Core that manages a development and research pilot program and coordinates with clinical and industry advisors. The P01 mechanism, typically reserved for multi-investigator center-scale efforts, reflects the scope of infrastructure the Gladstone team is assembling. The combination of quantitative infection-cycle assays, AI-guided phage selection, and human-relevant tissue models represents an attempt to address a persistent bottleneck in phage therapy development: the absence of standardized, predictive preclinical tools that can reliably translate to clinical outcomes. ESKAPE pathogens - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species - account for a substantial proportion of hospital-acquired infections globally and are associated with high rates of multidrug resistance. K. pneumoniae in particular has drawn research attention due to the diversity of its capsule types, which directly determine phage susceptibility and complicate the design of broadly effective phage preparations. NIAID's decision to fund a center structured around capsule typing and AI-guided tailspike engineering reflects the recognized complexity of matching phages to clinical bacterial isolates at scale. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Exclusive: biotech group leases 105,000 square feet in S.F. as it plans to hire 300 scientists. By Roland Li, Staff Writer March 25, 2026 Biomedical research nonprofit Gladstone Institutes has leased 105,000 square feet in the last major new building of San Francisco's Mission Bay, part of the company's expansion plans that include hiring 300 new scientists. The deal at 1450 Owens St. includes space for 30 new labs and is one of the city's biggest leases of 2026, so far. It includes the option for Gladstone to purchase the building in the future and is a block from its headquarters at 1650 Owens St. Get Digital Access and Stay Informed With Trusted Local News. Gladstone's work is increasingly focused on using artificial intelligence - a booming sector in Mission Bay - to speed up research around drug discovery. The new building will house the Gladstone Institute of Data Science and Biotechnology and the Gladstone-UCSF Institute of Genomic Immunology. Article continues below this ad "We embed the AI and technology with the biological questions," said Dr. Deepak Srivastava, president of Gladstone. "We are both inventors and rapid adopters of technology." Gladstone's hiring plans would increase its current staff of around 600 scientists by 50%. Research areas include heart disease, infectious diseases, cancer, and neurological diseases including Alzheimer's and Parkinson's. See more S.F. Chronicle on google. Make us a Preferred Source to get more of our news when you search. Gladstone is currently recruiting lab leaders from around the world. That's despite two major challenges in the past year: the Trump administration's hostility to foreign immigration and widespread federal research cuts. Article continues below this ad Around $80 million of Gladstone's $125 million annual budget comes from grants from the National Institutes of Health, and funding dropped by 10% last year, Srivastava said. "In the U.S. we've really benefited from the most brilliant minds coming here. That's certainly under threat," he said. Despite the obstacles, Gladstone is continuing its expansion plans, in part by seeking more philanthropic support. Starting in 2024, Gladstone sought to raise $350 million by 2029. Around $200 million has been raised to date. Major donors include real estate developer and former Giants owners Bob Lurie and wife Connie; real estate developer John Sobrato and wife Susan; former venture capitalist Bill Younger, who is chair of Gladstone's board, and wife Brenda; hedge fund manager William Fisher, who is the son of Gap's co-founders, and wife Sakurako; Divesh Makan, co-founder of Iconiq Capital, and Diksha Makan; and the Dolby family. "The work we're doing is too important to slow at this moment when we have greater opportunity (through technology). I just wasn't willing to slow down," Srivastava said. "Every day we go slower is more people dying." Gladstone was established in 1979 and is named for Jack David Gladstone, a real estate developer who left most of his fortune to biomedical research. The nonprofit was one of the first tenants in Mission Bay in 2004, alongside UCSF. "When I moved here, it was all abandoned warehouses. There was just two buildings. This growth is phenomenal," Srivastava said. Alexandria Real Estate Equities, a major biotech landlord, has also built numerous Mission Bay buildings including 1450 Owens St., which is the last major parcel in the area. DGA Architects and IwamotoScott Architecture designed the building. Alexandria doesn't typically start construction on new buildings until it secures an anchor tenant, but did so at 1450 Owens after requests from the city, said Joel Marcus, Alexandria's executive chairman. Construction started in 2022 and was completed in 2024. (Gladstone will build its own tenant improvements and plans to move in by early 2027.) Marcus called the building "a great place for innovative research," with state-of-the-art lab space. Around half of the building remains vacant, and Marcus said both biotech and AI tenants have shown interest in the remaining space. He called Mission Bay a "thriving metropolis" that now has biotech, AI, housing, and a major sports and entertainment complex in Chase Center. Still, the biotech industry remains in a downturn, with widespread layoffs and funding cuts. Though Gladstone is a nonprofit, it partners with for-profit companies to take drugs through clinical trials and eventual Food and Drug Administration approval. Srivastava is "starting to see the green shoots of a resurgence," with more drug approval activity and investments. "It's been a rough period," he said. "People are starting to see the convergence of AI and biotech is so powerful right now." Get inside access to the deals and developments transforming San Francisco and the Bay Area. March 25, 2026 Business Reporter Roland Li covers commercial real estate for the business desk, focusing on the Bay Area office and retail sectors. He was previously a reporter at San Francisco Business Times, where he won one award from the California News Publishers Association and three from the National Association of Real Estate Editors. He is the author of "Good Luck Have Fun: The Rise of eSports," a 2016 book on the history of the competitive video game industry. Before moving to the Bay Area in 2015, he studied and worked in New York. He freelanced for the Wall Street Journal, the New York Times and other local publications. His hobbies include swimming and urban photography.
Gladstone expands research footprint with 105,000 square feet of new laboratory space. Gladstone Institutes will open approximately 20 new laboratories in early 2027 at 1450 Owens Street. The building is part of the Alexandria Center(R) for Science and Technology - Mission Bay Megacampus(TM). (Image courtesy of Alexandria Real Estate Equities, Inc.) Gladstone Institutes has secured more than 105,000 square feet of future laboratory space in a newly constructed building at 1450 Owens Street, empowering its scientists with the tools and environment to create medicines of the future. Located a block from Gladstone's headquarters in San Francisco's Mission Bay neighborhood, the new space will be home to approximately 300 scientists across 20 labs, with state-of-the-art equipment and computational abilities, starting in early 2027. "We're at a revolutionary moment in science and medicine," says Deepak Srivastava, MD, president of Gladstone. "Driven by transformational technologies pioneered by our researchers and the explosive growth of computational power, we no longer have to accept disease - we can now envision prevention and cures. With an expansion into 1450 Owens Street, we will be writing the next chapter of medicine." Gladstone executed a long-term lease with the building's owner, operator, and developer, Alexandria Real Estate Equities, Inc., with an option to purchase the leased premises within the building in the future. "Gladstone is a prolific innovation engine at the forefront of developing new therapies to address some of the more than 10,000 diseases known to humankind that remain unsolved," says Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE). "We deeply value our nearly two-decade strategic relationship with Gladstone and are honored to welcome them as the anchor tenant at 1450 Owens Street in our Mission Bay cluster." The expansion is funded through Gladstone's five-year, $350 million capital campaign, Gladstone NOW. Launched in September 2024, the campaign is harnessing philanthropic power to scale wisely by adding lab space and multidisciplinary scientists; catalyze breakthroughs with high-risk, high-reward research; create a computational powerhouse to unlock the potential of artificial intelligence x biomedicine; and close the gap between the moment of discovery and the minute that cures and new therapies reach patients around the world. Major donors include the Connie and Bob Lurie Foundation, Susan and John Sobrato, the Younger Family Fund, Sakurako and William Fisher, Diksha and Divesh Makan, and the Dolby family. An environment for innovation. Gladstone moved into its current Mission Bay headquarters in 2004, pioneering the development of what is now one of the nation's leading life sciences hubs. The nearly 200,000-square-foot building at 1650 Owens Street has served as a launchpad for Gladstone's exceptional growth over the past two decades. This growth included the creation of two new institutes: the Gladstone Institute of Data Science and Biotechnology in 2018, led by Katie Pollard, PhD, and the Gladstone-UCSF Institute of Genomic Immunology in 2020, led by Alex Marson, MD, PhD. These will be the first to occupy the new space. Two of Gladstone's fast-growing institutes - one focused on AI and data science, and the other on immunotherapy development - will be co-located in the new building at 1450 Owens Street, just down the block from Gladstone's headquarters. (Image courtesy of Alexandria Real Estate Equities, Inc.) "Gladstone is at the forefront of leveraging artificial intelligence for scientific progress," Pollard says. "AI has completely reshaped research, the drug discovery process, and clinical trials, with the potential to dramatically lower the cost of care. We're excited to pioneer the next generation of biotechnologies in our new space to solve disease." The field of immunology is also at an inflection point, as scientists begin to understand how specific DNA sequences control the behavior of specialized cells comprising the human immune system. Along with this, extraordinary advances in DNA sequencing, CRISPR engineering, and synthetic biology are expanding knowledge about genetic regulation of immune cells and how to alter them to improve health. "In our new laboratories, we will design and produce tailored immunotherapies to treat cancer, autoimmune diseases, and infections," Marson says. "Already, we're marching toward progress. But with this new building, we can sprint toward it." A plan for the future. When Gladstone's data science and genomic immunology institutes move into 1450 Owens Street, valuable space will become available in the existing building at 1650 Owens Street, which is now exceeding capacity. Gladstone's three other institutes - focused on cardiovascular disease, neurological disease, and infectious disease - will have critical room for expansion to bring curative therapies to bear. Gladstone also maintains the possibility of expanding its existing building in the future to accommodate further growth while remaining fully in the Mission Bay district. "Our new facility will be among the crown jewels of the Bay Area biotech ecosystem when it comes online in early 2027," Srivastava says. "We look forward to co-locating our fast-growing immunotherapy and computational biology operations in the new space, and seizing the opportunity to recruit trailblazing scientists in each of our disease areas from around the world." For Media Kelly Quigley Director, Science Communications and Media Relations 415.734.2690 Email About Gladstone Institutes Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.